Seaweed supplement shows promise for cancer-related fatigue in small pilot trial
NCT ID NCT06295588
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This pilot study tests whether taking a seaweed supplement called fucoidan for 8 to 16 weeks can reduce fatigue and inflammation in cancer survivors. Researchers will enroll 40 adults who have completed cancer treatment within the last 10 years and still feel tired. The main goal is to see if the study is feasible, but they will also measure changes in fatigue, frailty, and blood markers of inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Rochester Medical Center
RECRUITINGRochester, New York, 14642, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fucoidan (a seaweed supplement)
What this could lead to
If it works, this could point toward a natural supplement to ease fatigue and inflammation in cancer survivors.
What could go wrong
This is a small, early pilot study with only 40 people. It's testing feasibility, not yet effectiveness, and results may not apply to all survivors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.